​

Sage Therapeutics (SAGE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SAGE Stock Forecast

Sage Therapeutics (SAGE) stock forecast, based on 31 Wall Street analysts, predicts a 12-month average price target of $13.80, with a high of $26.00 and a low of $5.00. This represents a 85.73% increase from the last price of $7.43.

$5 $10 $15 $20 $25 $30 High: $26 Avg: $13.8 Low: $5 Last Closed Price: $7.43

SAGE Stock Rating

Sage Therapeutics stock's rating consensus is Hold, based on 31 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (25.81%), 23 Hold (74.19%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 31 0 23 8 Strong Sell Sell Hold Buy Strong Buy

SAGE Price Target Upside V Benchmarks

TypeNameUpside
StockSage Therapeutics85.73%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--12
Avg Price Target--$13.67
Last Closing Price$7.43$7.43$7.43
Upside/Downside--83.98%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 253-15-119
Mar, 253-15--18
Feb, 253-14--17
Jan, 253-16-120
Dec, 242-17-120
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 07, 2025Brian AbrahamsRBC Capital$5.00$5.98-16.39%-32.71%
Nov 20, 2024Brian AbrahamsRBC Capital$4.00$4.91-18.53%-46.16%
Oct 30, 2024Yasmeen RahimiPiper Sandler$26.00$7.90229.11%249.93%
Oct 30, 2024George FarmerScotiabank$14.00$8.4865.09%88.43%
Oct 30, 2024Vamil DivanMizuho Securities$10.00$7.8627.23%34.59%
Oct 30, 2024Douglas TsaoH.C. Wainwright$14.00$8.4865.09%88.43%
Aug 14, 2024Joon LeeTruist Financial$13.00$7.9563.52%74.97%
Aug 06, 2024Sumant KulkarniCanaccord Genuity$9.00$8.881.35%21.13%
May 28, 2024Joel BeattyRobert W. Baird$15.00$11.9325.73%101.88%
Apr 25, 2024Joon LeeTruist Financial$18.00$13.5832.55%142.26%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 20, 2024RBC CapitalUnderperformSector Performupgrade
Oct 30, 2024Piper SandlerOverweightOverweighthold
Oct 30, 2024ScotiabankOutperformOutperformhold
Oct 30, 2024ScotiabankSector OutperformSector Outperformhold
Oct 30, 2024H.C. WainwrightNeutralNeutralhold
Oct 04, 2024ScotiabankSector OutperformSector Outperformhold
Oct 04, 2024RBC CapitalUnderperformSector Performdowngrade
Jul 30, 2024J.P. MorganUnderperformUnderperformhold
Jul 30, 2024Cowen & Co.BuyHolddowngrade

Financial Forecast

EPS Forecast

$-20 $-13 $-6 $1 $8 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.66$-7.68$-8.49$-9.05$-6.59----
Avg Forecast$-9.14$-7.89$-8.88$-9.63$-6.46$-3.73$-2.31$-1.74$-0.81
High Forecast$-4.33$-3.74$-3.02$-8.04$-5.97$-2.55$-1.41$-0.34$-0.41
Low Forecast$-18.46$-15.93$-16.59$-11.15$-7.01$-5.10$-3.28$-2.99$-1.71
Surprise %-227.57%-2.66%-4.39%-6.02%2.01%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.11B$6.31M$7.69M$86.45M$41.24M----
Avg Forecast$7.06M$6.47M$6.84M$69.47M$42.58M$89.95M$155.69M$168.57M$238.19M
High Forecast$12.60M$11.54M$11.42M$140.74M$45.44M$168.35M$156.81M$169.54M$441.52M
Low Forecast$4.20M$3.85M$3.37M$9.89M$40.53M$60.08M$154.57M$167.60M$148.15M
Surprise %15678.88%-2.44%12.33%24.46%-3.15%----

Net Income Forecast

$-5B $8B $21B $34B $47B $60B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$606.07M$-450.83M$-503.27M$-541.49M$-400.67M----
Avg Forecast$46.94B$-439.24M$-499.43M$-541.49M$-388.19M$-246.12M$-179.93M$-125.70M$-48.47M
High Forecast$56.49B$-351.39M$-399.54M$-433.19M$-357.09M$-152.72M$-84.61M$-20.44M$-24.65M
Low Forecast$37.39B$-527.09M$-599.31M$-649.79M$-419.29M$-305.45M$-196.06M$-178.85M$-102.26M
Surprise %-98.71%2.64%0.77%-3.21%----

SAGE Forecast FAQ

Is Sage Therapeutics stock a buy?

Sage Therapeutics stock has a consensus rating of Hold, based on 31 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 23 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Sage Therapeutics is a neutral investment for most analysts.

What is Sage Therapeutics's price target?

Sage Therapeutics's price target, set by 31 Wall Street analysts, averages $13.8 over the next 12 months. The price target range spans from $5 at the low end to $26 at the high end, suggesting a potential 85.73% change from the previous closing price of $7.43.

How does Sage Therapeutics stock forecast compare to its benchmarks?

Sage Therapeutics's stock forecast shows a 85.73% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Sage Therapeutics over the past three months?

  • April 2025: 15.79% Strong Buy, 0% Buy, 78.95% Hold, 0% Sell, 5.26% Strong Sell.
  • March 2025: 16.67% Strong Buy, 0% Buy, 83.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 17.65% Strong Buy, 0% Buy, 82.35% Hold, 0% Sell, 0% Strong Sell.

What is Sage Therapeutics’s EPS forecast?

Sage Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.73, marking a -43.40% decrease from the reported $-6.59 in 2024. Estimates for the following years are $-2.31 in 2026, $-1.74 in 2027, and $-0.81 in 2028.

What is Sage Therapeutics’s revenue forecast?

Sage Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $89.95M, reflecting a 118.10% increase from the reported $41.24M in 2024. The forecast for 2026 is $155.69M, followed by $168.57M for 2027, and $238.19M for 2028.

What is Sage Therapeutics’s net income forecast?

Sage Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-246M, representing a -38.57% decrease from the reported $-401M in 2024. Projections indicate $-180M in 2026, $-126M in 2027, and $-48.468M in 2028.